Associated Papers
Comprehensive clinical and immunologic characterization of Wiskott-Aldrich syndrome in Iran: a 10-year cohort study.
Esmaeilzadeh H et al.
Bmc Immunology, 2025
Unmasking Wiskott-Aldrich Syndrome in Adulthood in a Case of Long-Standing Bleeding, Infections, and Steroid-Induced Morbidity.
Dutta A
Cureus, 2025
Comorbidities in Mild WAS/XLT Require Lifelong Follow-Up and Consideration of Definitive Treatment.
Mallebranche C et al.
American Journal of Hematology, 2025
Inborn Error of WAS Presenting with SARS-CoV-2-Related Multisystem Inflammatory Syndrome in Children.
Drago E et al.
Journal of Clinical Immunology, 2024
A Non-targeted Proteomics Newborn Screening Platform for Inborn Errors of Immunity.
Shibata H et al.
Journal of Clinical Immunology, 2024
Accelerated death of megakaryocytes from Wiskott-Aldrich syndrome patients.
Obydennyi SI et al.
British Journal of Haematology, 2023
Utility of targeted next generation sequencing for inborn errors of immunity at a tertiary care centre in North India.
Rawat A et al.
Scientific Reports, 2022
Clinical and Genetic Spectrum of Inborn Errors of Immunity in a Tertiary Care Center in Southern India.
Lashkari HP et al.
Indian Journal of Pediatrics, 2022
Successful low-dose chemotherapy for refractory Epstein-Barr virus-related post-transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott-Aldrich syndrome.
Xi B et al.
Clinical Case Reports, 2021
Autoimmunity in Wiskott-Aldrich Syndrome: Updated Perspectives.
Sudhakar M et al.
The Application of Clinical Genetics, 2021
Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome.
Sereni L et al.
The Journal of Allergy and Clinical Immunology, 2019
Gene therapy for Wiskott-Aldrich syndrome: here to stay.
Candotti F
The Lancet. Haematology, 2019
Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F et al.
The Lancet. Haematology, 2019
When WAS Gene Diagnosis Is Needed: Seeking Clues Through Comparison Between Patients With Wiskott-Aldrich Syndrome and Idiopathic Thrombocytopenic Purpura.
Jin YY et al.
Frontiers in Immunology, 2019
B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome.
Castiello MC et al.
The Journal of Allergy and Clinical Immunology, 2015
Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature.
Senapati J et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2014
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.
Aiuti A et al.
Science (new York, N.y.), 2013
Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome.
Shin CR et al.
Bone Marrow Transplantation, 2012
Molecular basis of Wiskott-Aldrich syndrome in patients from India.
David S et al.
European Journal of Haematology, 2012
Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome.
Gulácsy V et al.
Molecular Immunology, 2011
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.
Albert MH et al.
Blood, 2010
Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome.
Davis BR et al.
Blood, 2008
Novel membrane cell projection defects in Wiskott-Aldrich syndrome B cells.
Andreu N et al.
International Journal of Molecular Medicine, 2007
The Wiskott-Aldrich syndrome: from genotype-phenotype correlation to treatment.
Moratto D et al.
Expert Review of Clinical Immunology, 2007
Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation.
Pai SY et al.
Bone Marrow Transplantation, 2006
Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro.
Dewey RA et al.
Experimental Hematology, 2006
Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome.
Wada T et al.
Blood, 2005
Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation.
Jin Y et al.
Blood, 2004
Flow cytometric determination of intracytoplasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations.
Kawai S et al.
Journal of Immunological Methods, 2002
Monocytes from Wiskott-Aldrich patients differentiate in functional mature dendritic cells with a defect in CD83 expression.
Allavena P et al.
European Journal of Immunology, 2001
Identification of WASP mutations in 14 Spanish families with Wiskott-Aldrich syndrome.
Fillat C et al.
American Journal of Medical Genetics, 2001
Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes.
Lemahieu V et al.
Human Mutation, 1999
Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.
Zhu Q et al.
Blood, 1997
Wiskott-Aldrich syndrome: no strict genotype-phenotype correlations but clustering of missense mutations in the amino-terminal part of the WASP gene product.
Schindelhauer D et al.
Human Genetics, 1996
The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene.
Zhu Q et al.
Blood, 1995
Unrelated donor BMT for Wiskott-Aldrich syndrome.
Lenarsky C et al.
Bone Marrow Transplantation, 1993
Novel mutations, no detectable mRNA and familial genetic analysis of the Wiskott-Aldrich syndrome protein gene in six Japanese patients with Wiskott-Aldrich syndrome.
Sasahara Y et al.
European Journal of Pediatrics, 0